Cicletanine References

Cicletanine
Clinical data
AHFS/ Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C03BX03 ( WHO) ;
Pharmacokinetic data
Protein binding	97.3%
Elimination half-life	7.9 h
Identifiers
	IUPAC name 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol;
CAS Number	89943-82-8 ;
PubChem CID	54910;
ChemSpider	49583 ;
UNII	CHG7QC509W;
KEGG	D03487 ;
ChEMBL	ChEMBL191886 ;
ECHA InfoCard	100.158.583
Chemical and physical data
Formula	C14H12ClNO2
Molar mass	261.71 g·mol−1
3D model ( JSmol)	Interactive image;
	SMILES Clc1ccc(cc1)C3OCc2c3cnc(c2O)C;
	InChI InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3 ; Key:CVKNDPRBJVBDSS-UHFFFAOYSA-N ;
	(verify)

Cicletanine is a furopyridine low-ceiling diuretic drug, usually used in the treatment of hypertension.^[1] The drug is manufactured by Ipsen and marketed by Recordati (in France) under the trade name Tenstaten.

It appears to be more potent in salt-sensitive hypertension.^[2]

Mechanism

It can inhibit protein kinase C.^[3]

References

^ Sassard J (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
^ Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". Journal of Hypertension. 18 (2): 209–215. doi: 10.1097/00004872-200018020-00012. PMID 10694190. S2CID 35374482.
^ Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension. 41 (3): 505–511. doi: 10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.

External links

Ipsen Corporation

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[1] Sassard J (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.

[pmid10694190-2] Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". Journal of Hypertension. 18 (2): 209–215. doi: 10.1097/00004872-200018020-00012. PMID 10694190. S2CID 35374482.

[pmid12623951-3] Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension. 41 (3): 505–511. doi: 10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.

[1]

[2]

[3]

Clinical data

AHFS/ Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C03BX03 ( WHO)
Pharmacokinetic data
Protein binding	97.3%
Elimination half-life	7.9 h
Identifiers
IUPAC name 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
CAS Number	89943-82-8^Y
PubChem CID	54910
ChemSpider	49583^Y
UNII	CHG7QC509W
KEGG	D03487^Y
ChEMBL	ChEMBL191886^Y
ECHA InfoCard	100.158.583
Chemical and physical data
Formula	C₁₄H₁₂ClNO₂
Molar mass	261.71 g·mol⁻¹
3D model ( JSmol)	Interactive image
SMILES Clc1ccc(cc1)C3OCc2c3cnc(c2O)C
InChI InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3^Y Key:CVKNDPRBJVBDSS-UHFFFAOYSA-N^Y
(verify)